|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:paclitaxel
|
|
gptkbp:activities
|
microtubule stabilizer
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1992
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
Paclitaxel
|
|
gptkbp:case_types
|
gptkb:healthcare_organization
ovarian cancer
|
|
gptkbp:clinical_trial
|
palliative care
Phase II
Phase III
Phase I
adjuvant therapy
neoadjuvant therapy
|
|
gptkbp:composed_of
|
semi-synthesis
total synthesis
extraction from plant
|
|
gptkbp:contraindication
|
pregnancy
neutropenia
severe hypersensitivity
lactation
|
|
gptkbp:developed_by
|
gptkb:Pacific_yew_tree
|
|
gptkbp:discovered_by
|
Monique Cragg
|
|
gptkbp:dissolved
|
insoluble in water
soluble in ethanol
soluble in dimethyl sulfoxide
|
|
gptkbp:excretion
|
urine
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Taxol
|
|
gptkbp:ingredients
|
C47 H51 N O14
|
|
gptkbp:interacts_with
|
CY P3 A4 inhibitors
CY P2 C8 inhibitors
|
|
gptkbp:invention
|
gptkb:2013
patented
|
|
gptkbp:is_atype_of
|
L01 C D01
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
13 hours
|
|
gptkbp:marketed_as
|
gptkb:Abraxane
gptkb:Taxol
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
Paclitaxel
|
|
gptkbp:produced_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:research_areas
|
drug development
oncology
pharmacology
chemotherapy
|
|
gptkbp:side_effect
|
nausea
allergic reactions
hair loss
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
33069-62-4
|